Hostname: page-component-8448b6f56d-xtgtn Total loading time: 0 Render date: 2024-04-19T01:08:25.881Z Has data issue: false hasContentIssue false

Serum Calcium in Prolonged Narcosis

Published online by Cambridge University Press:  19 February 2018

T. J. Hennelly
Affiliation:
Cardiff City Mental Hospital
E. D. Yates
Affiliation:
Biochemical Laboratory, Cardiff City Mental Hospital

Extract

Investigations into the possible causes of toxic symptoms arising during the course of prolonged somnifaine narcosis showed that a fall in serum calcium occurred during the course of the treatment (1). Previous investigations on blood calcium (3, 4, 5, 6, 15) made it clear that during barbiturate narcosis there was a fall of 10–20% of the normal value. Observations, however (7, 8, 9, 10), that therapeutic exhibition of insulin resulted in an increase in serum calcium suggested that no gross abnormality in calcium level was to be expected during the modified somnifaine-insulin-glucose treatment (2) practised in this hospital. The investigations here reported were undertaken to determine what fall in serum calcium occurred during this modified treatment, and to determine whether this fall was sufficient to cause toxic symptoms. If so the advisability of taking steps to avoid them could then be considered. The investigations showed a definite lowering in serum calcium during the course of treatment of psychotic patients by this method, and they suggested that somnifaine and insulin are only pseudo-antagonistic in their effect upon calcium metabolism. In the ten cases reported, a fall in serum calcium of from 3–20% has invariably been observed, the maximum being reached four to seven days after the beginning of the treatment.

Type
Part I.—Original Articles
Copyright
Copyright © Royal College of Psychiatrists, 1936 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Ström-Olsen, , Journ. Ment. Sci., 1933, lxxix, p. 638.CrossRefGoogle Scholar
2 Quastel, and Ström-Olsen, , Lancet, 1933, ccxxiv (i), pp. 464.CrossRefGoogle Scholar
3 Cloetta, and Thomann, , Arch. Exper. Path. Pharm., 1931, ciii, p. 260.Google Scholar
4 Fischer, , Schweiz. Arch. Neru. Psych., 1931–2, xxviii, p. 73.Google Scholar
5 Katzenelbogen, , Arch. Neur. Psych., 1930, xxiv, p. 525.CrossRefGoogle Scholar
6 Idem , ibid., 1932, xxvii, p. 154.Google Scholar
7 Staul, Gunther and Frölich, , Klin. Wochenschr., 1923, ii, p. 2337.Google Scholar
8 Davies, Dickens and Dodds, , Biochem. Journ., 1926, xx, p. 695.CrossRefGoogle Scholar
9 Brougher, , Amer. Journ. Physiol., 1927, lxxx, p. 411.CrossRefGoogle Scholar
10 Ellsworth, , Journ. Clin. Invest., 1930, viii, p. 139.CrossRefGoogle Scholar
11 Peters, and Van Slyke, , Quantitative Clinical Chemistry, ii, p. 767.Google Scholar
12 Idem , ibid., i, p. 815.Google Scholar
13 Freeman, Kant and Ivy, , Journ. Biol. Chem., 1935, cxii, p. 1.CrossRefGoogle Scholar
14 Darrow, and Cary, , ibid., 1934, cv, p. 327.Google Scholar
15 Michaels, , Arch. Neur. Psych., 1935, xxx, p. 362.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.